Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 3, 2008, Pages 239-242

  Actis, G C ^a   Pellicano, R ^a   Bugianesi, E ^a   Lagget, M ^a   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Hepatitis, autoimmune; Immunomodulators; Inflammatory bowel diseases; Steroids

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; MYCOPHENOLIC ACID;

ADULT; ARTICLE; ASPIRATION; AUTOIMMUNE HEPATITIS; COLON RESECTION; CROHN DISEASE; DAY HOSPITAL; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HOSPITAL ADMISSION; HOSPITAL SERVICE; HUMAN; LEUKAPHERESIS; LIVER BIOPSY; LIVER NODULE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; REMISSION; THROMBOSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DAY CARE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HOSPITALS, TEACHING; HUMANS; IMMUNOLOGIC FACTORS; MALE; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 57449107665     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Actis GC, Olivero A, Lagget M, Pellicano R, Smedile A, Rizzetto M. The practice of percutaneous liver biopsy in a gastrohepatology day hospital: a retrospective study on 835 biopsies. Dig Dis Sci 2007;52:2576-9.
2. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-9.
3. Actis GC, Ottobrelli A, Baldi S, Scappaticci E, Modena V, Fusaro E et al. Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report. Mount Sinai J Med 2005;72:136-40.
4. Bernstein CN, Wajda A, Svenson LV, Mackenzie A, Koehoorn M, Jackson M et al. The Epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68.
5. Wallace TM, Veldhuyzen van Zanten SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can J Gastroenterol 2001;15:21-8.
6. Bernal I, Domenech E, Garcia-Planella E, Marin L, Manosa M, Navarro M et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006;51:2165-9.
7. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporine: a long-term retrospective cohort study. BMC Gastroenterol 2007;7:13.
8. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
9. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007;25:1055-60.
10. Yamamoto-Furusho JK. Innovative therapeutics for inflammatory bowel disease. World J Gastroenterol 2007;13:1893-6.